JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Opus Genetics today and set a price target of $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Debanjana Chatterjee has given her Buy rating due to a combination of factors surrounding Opus Genetics’ promising developments. The company’s OPGx-BEST1 gene therapy program is showing potential, with early signs of structural benefits observed in preclinical models. This gene therapy targets patients with specific genetic profiles and intact photoreceptors, which could lead to significant improvements in their condition.
Moreover, the upcoming data release in the first quarter of 2026 is expected to provide insights from multiple patients, focusing on key clinical outcomes such as fluid resolution and retinal sensitivity improvements. Additionally, Opus Genetics is on track with its presbyopia program, which could result in a substantial milestone payment and future royalties. These strategic advancements and potential financial gains underpin Chatterjee’s optimistic outlook on the stock.
In another report released on October 16, Chardan Capital also initiated coverage with a Buy rating on the stock with a $9.00 price target.